Publications
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.
Analysing Global Immunisation Expenditure
15 April 2025
Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases.
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
Gene therapies represent a paradigm shift in medicine, offering the potential for significant improvements in both quality and longevity of life, by addressing the root genetic…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.
2023 OHE Annual Report to the Charity Commission
16 December 2024
We are pleased to submit our seventh submission to the Charity Commission for England and Wales since becoming a registered charity in December 2016.
Employer Costs from Respiratory Infections
16 December 2024
Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and address health inequities.
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
How does NICE’s severity modifier work? NICE implemented a new severity modifier in February 2022 as part of a wider update to its methods. Its aim…
A Spotlight on Haemophilia Therapies
3 October 2024
Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.